Richard Shen

Richard Shen is a Managing Director at Sedgwick Yard, a biotech venture capital firm focused on early-stage, cutting-edge therapeutics opportunities from emerging-growth companies and leading global academic institutions. In addition to Akamis Bio, Richard led the pre-Series A investment in DJS Antibodies, an Oxford biotech that was acquired by AbbVie in 2022. Richard has also helped incubate and manage InnDura Therapeutics and Endotope Biosciences, companies spun out of MIT/Dana Farber and Columbia University respectively.

Prior to Sedgwick Yard, Richard worked in the Investment Banking Division of Goldman Sachs and UBS in London and Hong Kong. Richard received his B.A. in Economics from University of Cambridge and MSc in Experimental & Translational Therapeutics from University of Oxford.